Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Povorcitinib on a skin condition known as vitiligo. Vitiligo is a condition where patches of skin lose their color, and this study specifically looks at a type called nonsegmental vitiligo, which is the most common form. The purpose of the study is to compare the effectiveness of Povorcitinib to a placebo in treating this condition over a period of 52 weeks.

Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The medication is taken orally in the form of a tablet.

The study will last for about a year, during which participants will be monitored to see if there is an improvement in their vitiligo. The main goal is to see if participants achieve a significant improvement in their skin condition by the end of the study. Participants will have regular check-ups and assessments to track their progress and ensure their safety throughout the trial.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be required to sign a consent form, confirming their understanding and willingness to participate.

    Participants must be at least 18 years old and have a clinical diagnosis of nonsegmental vitiligo.

  2. Step 2

    Discontinuation of current treatments

    Participants must stop using any treatments or procedures for vitiligo from the start of the study until the final safety follow-up visit.

  3. Step 3

    Medication administration

    Participants will receive either Povorcitinib or a placebo in the form of a tablet, taken orally.

    The study is designed to last for 52 weeks, during which the medication will be administered as per the study protocol.

  4. Step 4

    Regular assessments

    Throughout the study, participants will undergo regular assessments to monitor the effectiveness and safety of the treatment.

    These assessments will include measurements of vitiligo improvement using specific scoring indexes.

  5. Step 5

    End of study evaluation

    At the end of the 52-week period, participants will be evaluated to determine the proportion of those achieving significant improvement in vitiligo symptoms.

    The primary goal is to assess the improvement in the Face Vitiligo Area Scoring Index (F-VASI75) and other secondary endpoints.

Who can join the trial?

6 criteria

  • Must be able to understand and willing to sign a written consent form for the study.
  • Must be at least 18 years old at the time of giving consent.
  • Must have a clinical diagnosis of nonsegmental vitiligo, which is a type of skin condition that causes loss of skin color in patches.
  • Must agree to stop using all treatments for vitiligo from the start of the study until the final safety follow-up visit.
  • Must be willing to avoid becoming pregnant or fathering children during the study, following specific guidelines.
  • Must be willing and able to follow the study's rules and procedures, including having photographs taken.

Who cannot join the trial?

10 criteria

  • Participants who have a different type of vitiligo than the one being studied.
  • Individuals who are not adults, as the study is for adult participants only.
  • People who are not able to follow the study procedures or attend the required visits.
  • Participants who have other medical conditions that might interfere with the study.
  • Individuals who are pregnant or breastfeeding.
  • People who are currently participating in another clinical trial.
  • Participants who have had a recent major surgery or are planning to have one during the study.
  • Individuals who have a history of allergic reactions to the study medication.
  • People who are using certain medications that might affect the study results.
  • Participants who have a history of drug or alcohol abuse.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Povorcitinib is a medication being studied for its effectiveness in treating nonsegmental vitiligo, a condition that causes loss of skin color in patches. The trial aims to evaluate how well this medication works over a period of 52 weeks. Participants in the study will receive this medication to see if it can help improve their skin condition by restoring color to the affected areas.

What is already known about the treatment

Povorcitinib – Povorcitinib is administered orally and is currently being studied in clinical trials for its effectiveness in treating nonsegmental vitiligo, a condition characterized by loss of skin color in patches. The medication is in the Phase 3 stage of clinical trials, indicating it is being tested for safety and efficacy before potential approval for general medical use. Povorcitinib works by inhibiting specific enzymes involved in the immune response, which may help restore skin pigmentation. It is classified as a Janus kinase (JAK) inhibitor, a type of medication that targets pathways involved in inflammation and immune system regulation.

Investigated diseases

Vitiligo – Vitiligo is a skin condition characterized by the loss of pigment, resulting in white patches on various parts of the body. It occurs when the cells responsible for skin color, called melanocytes, are destroyed. The progression of vitiligo can vary; some people may experience slow and gradual spreading of the patches, while others might see rapid changes. The condition can affect any skin area, including the face, hands, and feet, and may also impact hair color. Although the exact cause is not fully understood, it is believed to involve genetic, autoimmune, and environmental factors. Vitiligo is not contagious and does not cause physical discomfort, but it can have psychological and social impacts.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506011-18-00Protocol codeINCB 54707-304Estimated enrolment444 patientsSponsorIncyte Corp.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).